The recent AACR Grantee Summit showcased the impactful research funded by AACR grants, including new targeted therapy approaches, miniaturized organoids to test cancer treatments, and a study of racial differences in communication related to...
A personalized mRNA vaccine reduces recurrence risk after melanoma surgery, and the FDA approves a drug combination for some people with metastatic prostate cancer.
In the latest edition of From the Bench, the AACR Blog explores recent innovative approaches to cancer research, including a method for limiting maternal-fetal transmission of certain cancer drugs, a virtual cancer cell model...
The October 2026 Editors’ Picks from AACR journals include findings on multiple primary cancers in World Trade Center responders, surgical de-escalation for atypical ductal hyperplasia, a modular CAR T-cell platform, an inhibitor that targets...
Results from a phase III trial showed that a cancer vaccine can improve outcomes for certain patients with melanoma, highlighting the potential of personalized vaccines to reshape cancer treatment.
At the recent AACR Conference on Pancreatic Cancer, researchers explored the complex interactions among tumor cells, neurons, and the tumor microenvironment, and what these discoveries could mean for future therapeutic strategies.
Studies reveal varying associations between ethnic enclaves and cancer outcomes, but researchers aim to identify community strengths that could improve care.
Families who travel far for treatment may face financial toxicity and insurance hurdles.
Breast cancer mortality rates have declined overall, but women who live in rural areas have not experienced the same progress as those in more populated areas.
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize for his pioneering discoveries that opened the door to the development of RAS-targeted therapies. Read...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More